Billy Wynne J.D.
Founder & Chairman
Billy Wynne is a nationally respected strategic advisor to elite health care organizations, including Fortune 500 companies, marquee health systems, and prominent foundations. After building one of Washington’s largest health policy practices, he and his team established Impact Health Policy Partners in 2018.
Prior to his private sector career, Billy served as Health Policy Counsel to the Senate Finance Committee where he was a key drafter and negotiator of several health care laws and assisted in the development of the health care reform “White Papers” that served as the basis for the Affordable Care Act. He has published several dozen articles in Health Affairs and other platforms, often appears on cable news, and is frequently cited by the New York Times, Washington Post, Politico, and other publications.
Billy is also a social impact entrepreneur, having founded Policy Hub, the only comprehensive aggregator of federal health policy analysis, and Awake, one of the world’s first entirely alcohol-free bar and spirit stores. He is a certified mindfulness meditation teacher and author of The Empty Path: Finding Fulfillment Through the Radical Art of Lessening, published by New World Library in March 2025.
Billy received a bachelor’s degree in Government from Dartmouth College and a law degree from the University of Virginia. He has served on several boards, including Operation Smile, Cherish Children Adoption International, the Zen Center of Denver, and Colorado’s Natural Medicine Advisory Board, which is implementing the state’s psychedelic therapy program.
Billy lives in Denver, CO with his wife, Christy, and their son, Harrison, and two shih-poos. Their daughter is in college
E&C Health Members Discuss Aduhelm, Pandemics, Rare Diseases in FDA User Fee Reauthorization Hearing
On Feb. 3, 2022, the Subcommittee on Health of the House Committee on Energy & Commerce (E&C) convened a hearing on the reauthorization of three Food and Drug Administration (FDA) user fee programs (hearing memo). These include the seventh reauthorization of the Prescription Drug User Fee Act (PDUFA VII), the third reauthorization of the Generic…